137 related articles for article (PubMed ID: 38007784)
41. [Correlation between the Expression of PD-L1 in Pleural Effusion of Lung Adenocarcinoma and the Clinicopathological Features and Molecular Changes].
Ma H; Jia J; Guo H; Zhao H; Wang C; Zhao L; Sun Y; Li W; Zhang Z
Zhongguo Fei Ai Za Zhi; 2020 Mar; 23(3):150-155. PubMed ID: 32209183
[TBL] [Abstract][Full Text] [Related]
42. PD-L1 score as a prognostic biomarker in asian early-stage epidermal growth factor receptor-mutated lung cancer.
Saw SPL; Ng WP; Zhou S; Lai GGY; Tan AC; Ang MK; Lim WT; Kanesvaran R; Ng QS; Jain A; Tan WL; Rajasekaran T; Chan JWK; Teh YL; Pang M; Yeo JC; Takano A; Ong BH; Tan EH; Tan SH; Skanderup AJ; Tan DSW
Eur J Cancer; 2023 Jan; 178():139-149. PubMed ID: 36436331
[TBL] [Abstract][Full Text] [Related]
43. Programmed Cell Death Ligand 1 Expression in Resected Non-Small Cell Lung Cancer.
Yu H; Brustugun OT; Ekman S; Botling J; La Fleur L; Micke P; Solberg S; Berglund A; Rivard C; Hirsch FR
Clin Lung Cancer; 2021 Jul; 22(4):e555-e562. PubMed ID: 33214079
[TBL] [Abstract][Full Text] [Related]
44. Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation.
Chen N; Fang W; Zhan J; Hong S; Tang Y; Kang S; Zhang Y; He X; Zhou T; Qin T; Huang Y; Yi X; Zhang L
J Thorac Oncol; 2015 Jun; 10(6):910-23. PubMed ID: 25658629
[TBL] [Abstract][Full Text] [Related]
45. Efficacy of ICI-based treatment in advanced NSCLC patients with PD-L1≥50% who developed EGFR-TKI resistance.
Li Y; Jiang H; Qian F; Chen Y; Zhou W; Zhang Y; Lu J; Lou Y; Han B; Zhang W
Front Immunol; 2023; 14():1161718. PubMed ID: 37266427
[TBL] [Abstract][Full Text] [Related]
46. [Expression of PD-1/PD-L1 in lung adenocarcinoma and correlation with epidermal growth factor receptor mutation status].
Wang Y; Da JP; Wang XH; Song AP; Chen H; Zhang HL; Chen S; Wang DW
Zhonghua Bing Li Xue Za Zhi; 2016 Dec; 45(12):854-858. PubMed ID: 28056301
[No Abstract] [Full Text] [Related]
47. Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer.
Azuma K; Ota K; Kawahara A; Hattori S; Iwama E; Harada T; Matsumoto K; Takayama K; Takamori S; Kage M; Hoshino T; Nakanishi Y; Okamoto I
Ann Oncol; 2014 Oct; 25(10):1935-1940. PubMed ID: 25009014
[TBL] [Abstract][Full Text] [Related]
48. DRD1 suppresses cell proliferation and reduces EGFR activation and PD-L1 expression in NSCLC.
Grant CE; Flis AL; Toulabi L; Zingone A; Rossi E; Aploks K; Sheppard H; Ryan BM
Mol Oncol; 2024 Jun; 18(6):1631-1648. PubMed ID: 38572507
[TBL] [Abstract][Full Text] [Related]
49. Prognostic Implication of PD-L1 Expression on Osimertinib Treatment for
Shiozawa T; Numata T; Tamura T; Endo T; Kaburagi T; Yamamoto Y; Yamada H; Kikuchi N; Saito K; Inagaki M; Kurishima K; Funayama Y; Miyazaki K; Koyama N; Furukawa K; Nakamura H; Kikuchi S; Ichimura H; Sato Y; Sekine I; Satoh H; Hizawa N
Anticancer Res; 2022 May; 42(5):2583-2590. PubMed ID: 35489768
[TBL] [Abstract][Full Text] [Related]
50. Comprehensive analysis of PD-L1 in non-small cell lung cancer with emphasis on survival benefit, impact of driver mutation and histological types, and archival tissue.
Wang CC; Huang KT; Chang HC; Tseng CC; Lai CH; Lan J; Liu TT; Huang CC; Lin MC
Thorac Cancer; 2022 Jan; 13(1):38-47. PubMed ID: 34841687
[TBL] [Abstract][Full Text] [Related]
51. Prognostic Significance of NSCLC and Response to EGFR-TKIs of EGFR-Mutated NSCLC Based on PD-L1 Expression.
Kobayashi K; Seike M; Zou F; Noro R; Chiba M; Ishikawa A; Kunugi S; Kubota K; Gemma A
Anticancer Res; 2018 Feb; 38(2):753-762. PubMed ID: 29374699
[TBL] [Abstract][Full Text] [Related]
52. Association of PD-L1 tumor proportion score ≥20% with early resistance to osimertinib in patients with EGFR-mutated NSCLC.
Hamakawa Y; Agemi Y; Shiba A; Ikeda T; Higashi Y; Aga M; Miyazaki K; Taniguchi Y; Misumi Y; Nakamura Y; Shimokawa T; Saigusa Y; Kobayashi N; Okamoto H; Kaneko T
Cancer Med; 2023 Sep; 12(17):17788-17797. PubMed ID: 37548381
[TBL] [Abstract][Full Text] [Related]
53. Strong Programmed Death Ligand 1 Expression Predicts Poor Response and De Novo Resistance to EGFR Tyrosine Kinase Inhibitors Among NSCLC Patients With EGFR Mutation.
Su S; Dong ZY; Xie Z; Yan LX; Li YF; Su J; Liu SY; Yin K; Chen RL; Huang SM; Chen ZH; Yang JJ; Tu HY; Zhou Q; Zhong WZ; Zhang XC; Wu YL
J Thorac Oncol; 2018 Nov; 13(11):1668-1675. PubMed ID: 30056164
[TBL] [Abstract][Full Text] [Related]
54. Farnesoid X Receptor Constructs an Immunosuppressive Microenvironment and Sensitizes FXR
You W; Li L; Sun D; Liu X; Xia Z; Xue S; Chen B; Qin H; Ai J; Jiang H
Cancer Immunol Res; 2019 Jun; 7(6):990-1000. PubMed ID: 30975694
[TBL] [Abstract][Full Text] [Related]
55. B7-1 and programmed cell death-ligand 1 in primary and lymph node metastasis lesions of non-small cell lung carcinoma.
Yamada T; Miki Y; Suzuki M; Kondoh O; Saito-Koyama R; Ono K; Okada Y; Sasano H
Cancer Med; 2022 Jan; 11(2):479-491. PubMed ID: 34907653
[TBL] [Abstract][Full Text] [Related]
56. Triptolide reduces PD-L1 through the EGFR and IFN-γ/IRF1 dual signaling pathways.
Xie Y; Ding J; Gao J; Zhang J; Cen S; Zhou J
Int Immunopharmacol; 2023 May; 118():109993. PubMed ID: 36931170
[TBL] [Abstract][Full Text] [Related]
57. Clinicopathological analysis and prognostic significance of programmed cell death-ligand 1 protein and mRNA expression in non-small cell lung cancer.
Kim H; Kwon HJ; Park SY; Park Y; Park E; Chung JH
PLoS One; 2018; 13(6):e0198634. PubMed ID: 29856861
[TBL] [Abstract][Full Text] [Related]
58. [Comparative Study of PD-L1 Expression in Different Sites of
Non-small Cell Lung Cancer].
Huang X; Wu J; Zhou L; Song Z; Xu W; Jia L; Diao X; Wu Q; Lin D
Zhongguo Fei Ai Za Zhi; 2022 May; 25(5):303-310. PubMed ID: 35570146
[TBL] [Abstract][Full Text] [Related]
59. Programmed death-ligand 1 expression and T790M status in EGFR-mutant non-small cell lung cancer.
Hata A; Katakami N; Nanjo S; Okuda C; Kaji R; Masago K; Fujita S; Yoshida H; Zama K; Imai Y; Hirata Y
Lung Cancer; 2017 Sep; 111():182-189. PubMed ID: 28838391
[TBL] [Abstract][Full Text] [Related]
60. Real-world outcomes of anti-PD1 antibodies in platinum-refractory, PD-L1-positive recurrent and/or metastatic non-small cell lung cancer, and its potential practical predictors: first report from Korean Cancer Study Group LU19-05.
Park JH; You GL; Ahn MJ; Kim SW; Hong MH; Han JY; Ock CY; Lee JS; Oh IJ; Lee SY; Kim CH; Min YJ; Choi YH; Ryu JS; Park SH; Ahn HK; Shim BY; Lee KH; Lee SY; Kim JS; Yi J; Choi SK; An H; Kang JH
J Cancer Res Clin Oncol; 2021 Aug; 147(8):2459-2469. PubMed ID: 33523301
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]